Twin deals to give NovaDx osteoporosis "monopoly"
This article was originally published in Clinica
NovaDx International (Canada) has announced two agreements which it claims will give it "an almost exclusive monopoly" on osteoclast-based blood tests for osteoporosis. In addition to a letter of intent signed with Harvard affiliate Forthsyth Dental Centre, the Vancouver company has been granted the right of refusal by the University of Texas to osteoclast proteins identified and developed by Dr G David Roodman.
You may also be interested in...
The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.